scholarly journals A systematic review of transfusion-associated graft-versus-host disease

Blood ◽  
2015 ◽  
Vol 126 (3) ◽  
pp. 406-414 ◽  
Author(s):  
Ilana Kopolovic ◽  
Jackie Ostro ◽  
Hideki Tsubota ◽  
Yulia Lin ◽  
Christine M. Cserti-Gazdewich ◽  
...  
Keyword(s):  
Systematic Review ◽  
At Risk ◽  
Graft Versus Host Disease ◽  
Hla Antigens ◽  
Host Disease ◽  
Graft Versus Host ◽  
Key Points ◽  
Blood Irradiation ◽  
Current Guidelines ◽  
Donor Lymphocytes

Key Points Fifty percent of TA-GVHD cases occur in patients who would not be predicted to be at risk for TA-GVHD by current guidelines for blood irradiation. Donor lymphocytes whose HLA antigens are all shared by the recipient dominate in TA-GVHD cases, particularly in immune-competent recipients.

scholarly journals Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT

2019 ◽  
Vol 3 (21) ◽  
pp. 3287-3296
Author(s):  
Yu Akahoshi ◽  
Hideki Nakasone ◽  
Koji Kawamura ◽  
Machiko Kusuda ◽  
Shunto Kawamura ◽  
...  
Keyword(s):  
At Risk ◽  
High Risk ◽  
Graft Versus Host Disease ◽  
Binding Protein ◽  
Liver Graft ◽  
Host Disease ◽  
Allogeneic Hsct ◽  
Graft Versus Host ◽  
Key Points ◽  
Patients At Risk

Key Points M2BPGi is increased in patients with liver graft-versus-host disease, especially in those at high risk for late NRM after allogeneic HSCT. WFA+-M2BP–positive macrophages are found in liver graft-versus-host disease, supporting these cells as a responder of this glycoprotein.

Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease

Blood ◽  
2014 ◽  
Vol 123 (24) ◽  
pp. 3832-3842 ◽  
Author(s):  
Silvia Spoerl ◽  
Nimitha R. Mathew ◽  
Michael Bscheider ◽  
Annette Schmitt-Graeff ◽  
Sophia Chen ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Key Points

Key Points We report that ruxolitinib reduces murine GVHD via increased Treg numbers. We demonstrate the potent activity of ruxolitinib treatment in patients with corticosteroid-refractory GVHD.

Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation

Blood ◽  
2013 ◽  
Vol 121 (18) ◽  
pp. 3745-3758 ◽  
Author(s):  
Emily Blyth ◽  
Leighton Clancy ◽  
Renee Simms ◽  
Chun K. K. Ma ◽  
Jane Burgess ◽  
...  
Keyword(s):  
T Cells ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Allogeneic Stem Cell Transplantation ◽  
Organ Damage ◽  
Host Disease ◽  
Graft Versus Host ◽  
Key Points

Key Points Infusion of CMV-specific T cells early posttransplant does not increase acute or chronic graft-versus-host disease. CMV-specific T cells early posttransplant reduce the need for pharmacotherapy without increased rates of CMV-related organ damage.

Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review

2021 ◽  
pp. 101520
Author(s):  
Moazzam Shahzad ◽  
Sibgha Gull Chaudhary ◽  
Abdul Basit ◽  
Connor Thellman ◽  
Liza Rodriguez ◽  
...  
Keyword(s):  
Systematic Review ◽  
Graft Versus Host Disease ◽  
Case Series ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants

2018 ◽  
Vol 2 (9) ◽  
pp. 1022-1031 ◽  
Author(s):  
Anita J. Kumar ◽  
Soyoung Kim ◽  
Michael T. Hemmer ◽  
Mukta Arora ◽  
Stephen R. Spellman ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Unrelated Donor ◽  
Host Disease ◽  
Graft Versus Host ◽  
Sibling Donor ◽  
Female Sibling ◽  
Key Points

Key Points Compared with parous female sibling donors, male URDs confer more aGVHD in all patients and more cGVHD in females. There was no difference in survival, relapse, or transplant mortality between recipients of parous female sibling or male URD grafts.

scholarly journals Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice

Blood ◽  
2017 ◽  
Vol 129 (20) ◽  
pp. 2737-2748 ◽  
Author(s):  
Qingrong Huang ◽  
Shan He ◽  
Yuanyuan Tian ◽  
Yuting Gu ◽  
Pan Chen ◽  
...  
Keyword(s):  
T Cells ◽  
Protein Stability ◽  
Graft Versus Host Disease ◽  
Hsp90 Inhibition ◽  
Host Disease ◽  
Graft Versus Host ◽  
Alloreactive T Cells ◽  
Graft Versus Leukemia ◽  
Key Points ◽  
And Function

Key Points Ezh2 requires Hsp90 to maintain Ezh2 protein stability and function in alloreactive T cells. Pharmacological inhibition of Hsp90 destabilizes Ezh2 protein in alloreactive T cells and reduces GVHD but preserves graft-versus-leukemia effects.

scholarly journals IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling

Blood ◽  
2019 ◽  
Vol 134 (23) ◽  
pp. 2092-2106 ◽  
Author(s):  
Andrew N. Wilkinson ◽  
Karshing Chang ◽  
Rachel D. Kuns ◽  
Andrea S. Henden ◽  
Simone A. Minnie ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cells ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Key Points ◽  
Donor T Cells ◽  
Principal Source

Key Points DCs are the principal source of IL-6 dysregulation after alloSCT. IL-6–dependent GVHD is driven by classical signaling of IL-6R on donor T cells but is regulated by trans signaling.

scholarly journals Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease

Blood ◽  
2017 ◽  
Vol 129 (24) ◽  
pp. 3256-3261 ◽  
Author(s):  
Yi-Bin Chen ◽  
Miguel-Angel Perales ◽  
Shuli Li ◽  
Maria Kempner ◽  
Carol Reynolds ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Phase 1 ◽  
Multicenter Trial ◽  
Brentuximab Vedotin ◽  
Host Disease ◽  
Graft Versus Host ◽  
Key Points ◽  
Steroid Refractory ◽  
Acute Graft

Key Points BV has activity for SR-aGVHD. The MTD of BV was 0.8 mg/kg every 2 weeks for 4 doses.

Sign in / Sign up

Export Citation Format

Share Document